Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Other financing activities: 2020-2024

Historic Other financing activities for Keros Therapeutics (KROS) over the last 1 years, with Sep 2024 value amounting to $130,000.

  • Keros Therapeutics' Other financing activities rose 381.48% to $130,000 in Q3 2024 from the same period last year, while for Sep 2024 it was $324,000, marking a year-over-year decrease of 1.22%. This contributed to the annual value of $171,000 for FY2024, which is 81.91% up from last year.
  • Latest data reveals that Keros Therapeutics reported Other financing activities of $130,000 as of Q3 2024, which was up 94.03% from $67,000 recorded in Q4 2023.
  • Keros Therapeutics' Other financing activities' 5-year high stood at $219,000 during Q1 2020, with a 5-year trough of $8,000 in Q2 2020.
  • Moreover, its 2-year median value for Other financing activities was $67,000 (2023), whereas its average is $74,667.
  • As far as peak fluctuations go, Keros Therapeutics' Other financing activities tumbled by 48.19% in 2021, and later skyrocketed by 381.48% in 2024.
  • Keros Therapeutics' Other financing activities (Quarterly) stood at $193,000 in 2020, then crashed by 48.19% to $100,000 in 2021, then reached $67,000 in 2023, then soared by 381.48% to $130,000 in 2024.
  • Its Other financing activities stands at $130,000 for Q3 2024, versus $67,000 for Q4 2023 and $27,000 for Q3 2023.